This review highlights tirzepatide, a novel dual agonist of GLP-1 and GIP receptors, which has demonstrated significant improvements in glycemic control, weight loss, and potential cardiovascular and renal benefits, marking it as a promising advancement in T2D treatment
Brazil's National Health Surveillance Agency (Anvisa) has approved the first semaglutide slimming pen produced in the country
Zhang X, Chang E, Fu Y, Liu X, Xu J, Wu Y, Wang A, Dong X, Miao S
Its activation contributes to retatrutides enhanced weight loss compared to GLP-1-only medications, but also influences alcohol absorption patterns through effects on gut motility
However, correlation analysis suggested that more body weight reduction was associated with less AHI improvement in patients with severe OSA
Compounding pharmacies are required to demonstrate through challenge testing that the product maintains sterility and is free of germs for a minimum of 28 days after first puncture